Laurus Labs Ltd IPO Message Board (Page 65)

Apply, Apply , Apply very good IPO. Forget Sleepwell

Dear Sir,
Please tell me wt about the Lauras Labs Ltd . shall i invest in this IPO.
B''coz i m new in market..
Plz reply sir...

Kabali ji,

We can blindly apply for this IPO. go and apply. in this year this is the best IPO.It will give morethan 50% returns on listing. enjoy:).

Gmp???

whether applying for HNI is same as retail investors

I meant EPS as seen in FY 15-16 Annual Report from Lauras Labs Website

Septa sir :- green light
Arjun patel:- ?
Eagleye:- ?

Its confusing, EPS on Laurus Labs website for FY15-16 annualised shows as 89. This implies P/E of less than 5 on upper band. Face Value of Shares is 10 in Annual report, and it''s same even in IPO. Please clarify, I have read elsewhere that asking PE at higher end is near 20. How is this? Can anyone clarify, going by their growth Full EPS for FY16-17 may be close to 110

LLL Very good ipo after endurance..
A p p l a y

THE BEST IPO FOR 2016 AT 428 PRICE
APPLY IN FULL FORCE my fair price comes to Rs 561
In my analysis i find this a very good IPO a company which looks a Net profit in excess of 200 cr 2017 even if CAGR is one third of what it achieved in last 5 years which was 60% plus so even at 20% will get to 200 Cr profit

it will list at 500 plus IMO

Initial Cash Flow:      $1,64,00,00,000                   
                        
Years:      1-5      6-10            
Growth Rate:      20%      11%            
                        
Terminal Growth Rate:      5%            Discount Rate:      10%
                        
Shares Outstanding:      10,57,56,250             Margin of Safety:      25%
Debt Level:                        
                        
Year      Flows      Growth      Value      
1      1,96,80,00,000       20%      $1,78,90,90,909       
2      2,34,19,20,000       19%      $1,93,54,71,074       
3      2,76,34,65,600       18%      $2,07,62,32,607       
4      3,23,32,54,752       17%      $2,20,83,56,500       
5      3,75,05,75,512       16%      $2,32,88,12,309       
6      4,31,31,61,839       15%      $2,43,46,67,414       
7      4,91,70,04,497       14%      $2,52,32,00,775       
8      5,55,62,15,081       13%      $2,59,20,15,341       
9      6,22,29,60,891       12%      $2,63,91,42,893       
10      6,90,74,86,589       11%      $2,66,31,35,101       
                        
                        
Terminal Year      $7,25,28,60,918                   
                        
PV of Year 1-10 Cash Flows:                  $23,19,01,24,925       
                        
Terminal Value:                  $55,92,58,37,125       
                        
Total PV of Cash Flows:                  $79,11,59,62,050       
                        
Number of Shares:                  10,57,56,250       
                        
Intrinsic Value (IV):                  $748.10       
                        
Margin of Safety IV:                  $561.07       
                        
What Percentage of IV comes from                   71%      
the Terminal Value:                        

Septaji,
You are providing valuable information.
Can you explain how you got Terminal Value: $55,92,58,37,125 ? Basically I want to understand the formula.

Sir,
I understood the Net present value calculation by yearwise discounting from certain rates ...only thing i am not sure is the inital cash inflow of 1st Year that you took of 164 Cr ... Do you took that by multiplying 143 crores PAT to assumed average growth rate of 15% ( 143.15 X 115% ) = 165 Cr...Am i correct in arriving at your figure of intial cash flow of 1st Year...?
also do you generally take into account & add back depreciation & other non cash expenses, amortizations etc (since R&D in pharma sector is a capex & significant factor) to take the intial cash inflow?

whereee isss egleye.......

You have used the wrong formula, rather than using it simply add by GP, you will get your mistake

While it is certainly a good ipo, but valuations are not cheap, it has been offered at 28x FY17 eps and 11x FY17 EV/EBIDTA, which in my opinion is a bit high. Please dont go by FY16 numbers, more equity has been issued in july and some more primary is being raised in the ipo.

I expect FY17, 18 and FY19 eps to be 15, 24 and 32 so it is a long term story certainly but immediate listing gains curbed because of expensive pricing.

Risks: Company is net importer, so forex will be a pin for the company. Also, hepc is under pricing control in india, aids is dependent on tenders.

look at the DRHP updated one.. It was shared during analyst meet which had results of september quarter. I quote the new eps from that

Got it, since they are issuing new shares, the outstanding shares will expand in the IPO hence diluting the EPS compared to what it was at FY15-16. At the IPO stage, since new shares are being issued, I assume EPS to be in range of 20s, which is placing it at a P/E of 21-22. This is still reasonable considering the high growth Laurus has delivered. Not to miss is it''s 50% global leadership/market share in Anti Retrovirals. This is phenomenal for any start up to achieve in a decade

@Silapathar - Many thanks for clarifying, I do not have the link to their RHP and yet to take a look at it. Should be available close to IPO dates

Can any one apply for HNI same as Retail investors or this require any special mode for applying

what is premiun lauras lab

Sorry first word is for by mistake it typed fo. Pl. read it for. Thanks.

Fo one time subsciption in etail how much application will be needed ? And in retail how much time can be subscribrd in present market and economical condition ?

Listing > 600

Hi everyone .... I am new ... Should I invest in this IPO??

Go for it, though there will be less chance of allotment as there is going to be huge bidding.

Septa ji fair value calculation of lauras labs please

i have done it mate apply with full force

Very useful information and strong IPO to apply.we will get more than 60% gains in this IPO.